Search

Your search keyword '"Zimmerman, Richard K"' showing total 1,028 results
Start Over Author "Zimmerman, Richard K"
1,028 results on '"Zimmerman, Richard K"'

2. Work Attendance with Acute Respiratory Illness Before and During COVID-19 Pandemic, United States, 2018-2022

Author

Ahmed, Faruque, Nowalk, Mary Patricia, Zimmerman, Richard K., Bear, Todd, Grijalva, Carlos G., Talbot, H. Keipp, Florea, Ana, Tartof, Sara Y., Gaglani, Manjusha, Smith, Michael, McLean, Huong Q., King, Jennifer P., Martin, Emily T., Monto, Arnold S., Phillips, C. Hallie, Wernli, Karen J., Flannery, Brendan, Chung, Jessie R., and Uzicanin, Amra

Subjects
Epidemics -- Statistics -- Risk factors -- United States, Respiratory tract diseases -- Statistics -- Risk factors, Influenza -- Statistics -- Risk factors, Presenteeism (Labor) -- Statistics -- Health aspects, Health
Abstract

COVID-19 cases in the United States, first reported on January 22, 2020, began to increase in March 2020 (1). The pandemic resulted in a substantial number of employed persons being [...]

Published
2023
Full Text
View/download PDF

3. Trends in HPV vaccine administration and HPV vaccine coverage in children by race/ethnicity and socioeconomic status during the COVID-19 pandemic in an integrated health care system in California

Author

Chao, Chun R, Xu, Lanfang, Cannizzaro, Nancy, Bronstein, David, Choi, Yunsun, Riewerts, Robert, Mittman, Brian, Zimmerman, Richard K, Gilkey, Melissa, Glenn, Beth, Shen, Ernest, Hsu, Chunyi, and Hahn, Erin E

Subjects
Paediatrics, Biomedical and Clinical Sciences, HPV and/or Cervical Cancer Vaccines, Infectious Diseases, Vaccine Related, Immunization, Prevention, Cancer, Sexually Transmitted Infections, Prevention of disease and conditions, and promotion of well-being, 3.4 Vaccines, Infection, Good Health and Well Being, Child, Humans, Papillomavirus Vaccines, Pandemics, Papillomavirus Infections, Ethnicity, COVID-19, Vaccination, Social Class, California, Delivery of Health Care, Integrated, Adolescent health, Covid-19, Health behavior, Human papillomavirus, Vaccine, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Virology, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundWe sought to evaluate the trends of HPV vaccination between 03/2019-09/2021 and whether the impact of the COVID pandemic on HPV vaccination varied by race/ethnicity and neighborhood deprivation index (NDI).MethodsElectronic medical records at Kaiser Permanente Southern California were used to assess monthly volume of HPV vaccine doses administered among children aged 9-12.9yrs, and up-to-date coverage (% vaccinated) by age 13 between 03/2019-09/2021. Modified Poisson models were used to evaluate the interactions between race/ethnicity, NDI and the pandemic periods on HPV vaccine coverage.ResultsHPV vaccine doses administered in 2020/2021 have returned to the 2019 level after the initial drop. The average up-to-date coverage in 05/2021-09/2021 (54.8%) remained lower than the pre-pandemic level (58.5%). The associations between race/ethnicity, NDI and HPV vaccine coverage did not vary due to the pandemic.ConclusionHPV vaccine promotion efforts are needed to address COVID-19 pandemic's lasting impact on HPV vaccination coverage.

Published
2022

7. Relationship between Telework Experience and Presenteeism during COVID-19 Pandemic, United States, March-November 2020

Author

Shafer, Livvy, Ahmed, Faruque, Kim, Sara, Wernli, Karen J., Jackson, Michael L., Nowalk, Mary Patricia, Bear, Todd, Zimmerman, Richard K., Martin, Emily T., Monto, Arnold S., Gaglani, Manjusha, Reis, Michael, Chung, Jessie R., Flannery, Brendan, and Uzicanin, Amra

Subjects
Epidemics -- Surveys -- United States, Telecommuting -- Surveys -- Health aspects, Presenteeism (Labor) -- Surveys -- Health aspects, Telecommuting, Health
Abstract

In response to the then-evolving COVID-19 pandemic, a public health emergency was declared in the United States on January 31, 2020, and several closure and containment policies were subsequently put [...]

Published
2023
Full Text
View/download PDF

8. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021

Author

Tenforde, Mark W, Olson, Samantha M, Self, Wesley H, Talbot, H Keipp, Lindsell, Christopher J, Steingrub, Jay S, Shapiro, Nathan I, Ginde, Adit A, Douin, David J, Prekker, Matthew E, Brown, Samuel M, Peltan, Ithan D, Gong, Michelle N, Mohamed, Amira, Khan, Akram, Exline, Matthew C, Files, D Clark, Gibbs, Kevin W, Stubblefield, William B, Casey, Jonathan D, Rice, Todd W, Grijalva, Carlos G, Hager, David N, Shehu, Arber, Qadir, Nida, Chang, Steven Y, Wilson, Jennifer G, Gaglani, Manjusha, Murthy, Kempapura, Calhoun, Nicole, Monto, Arnold S, Martin, Emily T, Malani, Anurag, Zimmerman, Richard K, Silveira, Fernanda P, Middleton, Donald B, Zhu, Yuwei, Wyatt, Dayna, Stephenson, Meagan, Baughman, Adrienne, Womack, Kelsey N, Hart, Kimberly W, Kobayashi, Miwako, Verani, Jennifer R, Patel, Manish M, Amosu, Omowunmi, Armbruster, Brent, Aston, Valerie, Bernardo, Marianne, Bowers, Robert, De Souza, Leslie, Friedel, Jennifer, Gardner, Kevin, Goff, Jennifer, Gordon, Alexandra June, Hendrickson, Audrey, Hicks, Madeline, Howell, Michelle, Johnson, Jakea, Jorgensen, Jeffrey, Karow, Sarah, Kozikowski, Lori, Krol, Olivia, Landreth, Leigha, LaRose, Mary, Lopez, Brenda, York, New, Luong, Andrea, McClellan, Bob, Maruggi, Ellen, Miller, Karen, Nair, Rahul, Parks, Lisa, Peers, Jennifer, Perez, Cynthia, Rivera, Adreanne, Roque, Jonasel, Santana, Andres, Scharber, Tyler, Silverman, Emma, Tozier, Michael, Tzehaie, Hiwet, Zouyed, Zachary, Arroliga, Alejandro, Bagiatis, Alicia, Balasubramani, GK, Cheng, Caroline K, Eng, Heather, Ghamande, Shekhar, Herrick, Judy, Hoffman, Eric, Hughes, Kailey, Lamerato, Lois E, Lauring, Adam S, McKillop, Amanda, McNeal, Tresa, McSpadden, EJ, Midturi, John, Mutnal, Manohar, and Nowalk, Mary Patricia

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Immunization, Vaccine Related, 3.4 Vaccines, Prevention of disease and conditions, and promotion of well-being, Good Health and Well Being, Aged, COVID-19, COVID-19 Vaccines, Female, Hospitalization, Humans, Male, Risk Assessment, Treatment Outcome, United States, Vaccination Coverage, Vaccines, Synthetic, IVY Network, HAIVEN Investigators, General & Internal Medicine
Abstract

Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first COVID-19 vaccines approved for use under an Emergency Use Authorization (EUA) in the United States (1-3). In an evaluation at 24 hospitals in 14 states,* the effectiveness of partial or full vaccination† with Pfizer-BioNTech or Moderna vaccines against COVID-19-associated hospitalization was assessed among adults aged ≥65 years. Among 417 hospitalized adults aged ≥65 years (including 187 case-patients and 230 controls), the median age was 73 years, 48% were female, 73% were non-Hispanic White, 17% were non-Hispanic Black, 6% were Hispanic, and 4% lived in a long-term care facility. Adjusted vaccine effectiveness (VE) against COVID-19-associated hospitalization among adults aged ≥65 years was estimated to be 94% (95% confidence interval [CI] = 49%-99%) for full vaccination and 64% (95% CI = 28%-82%) for partial vaccination. These findings are consistent with efficacy determined from clinical trials in the subgroup of adults aged ≥65 years (4,5). This multisite U.S. evaluation under real-world conditions suggests that vaccination provided protection against COVID-19-associated hospitalization among adults aged ≥65 years. Vaccination is a critical tool for reducing severe COVID-19 in groups at high risk.

Published
2021

10. Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness--United States

Author

Frutos, Aaron M., Price, Ashley M., Harker, Elizabeth, Reeves, Emily L., Ahmad, Haris M., Murugan, Vel, Martin, Emily T., House, Stacey, Saade, Elie A., Zimmerman, Richard K., Gaglani, Manjusha, Wernli, Karen J., Walter, Emmanuel B., Michaels, Marian G., Staat, Mary A., Weinberg, Geoffrey A., Selvarangan, Rangaraj, Boom, Julie A., Klein, Eileen J., Halasa, Natasha B., Ginde, Adit A., Gibbs, Kevin W., Zhu, Yuwei, Self, Wesley H., Tartof, Sara Y., Klein, Nicola P., Dascomb, Kristin, DeSilva, Malini B., Weber, Zachary A., Yang, Duck-Hye, Ball, Sarah W., Surie, Diya, DeCuir, Jennifer, Dawood, Fatimah S., Moline, Heidi L., Toepfer, Ariana P., Clopper, Benjamin R., Link-Gelles, Ruth, Payne, Amanda B., Chung, Jessie R., Flannery, Brendan, Lewis, Nathaniel M., Olson, Samantha M., Adams, Katherine, Tenforde, Mark W., Garg, Shikha, Grohskopf, Lisa A., Reed, Carrie, and Ellington, Sascha

Subjects
United States. National Institutes of Health, Merck & Company Inc., Pfizer Inc., Vaccination -- Health aspects, Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Influenza vaccines -- Health aspects, Influenza -- Health aspects, Medical colleges -- Health aspects, Children -- Health aspects, Health, Vanderbilt University. Medical Center
Abstract

Introduction CDC's Advisory Committee on Immunization Practices recommends annual influenza vaccination for all persons aged [greater than or equal to]6 months (1). During previous influenza seasons, influenza vaccination prevented hundreds [...]

Published
2024

15. Changes in the cost‐effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults.

Author

Wateska, Angela R., Nowalk, Mary Patricia, Altawalbeh, Shoroq M., Lin, Chyongchiou J., Harrison, Lee H., Schaffner, William, Zimmerman, Richard K., and Smith, Kenneth J.

Subjects
STREPTOCOCCAL disease prevention, MEDICAL protocols, IMMUNIZATION, STATISTICAL models, QUALITY-adjusted life years, COST effectiveness, RESEARCH funding, AFRICAN Americans, VACCINATION, DECISION making, COST benefit analysis, VACCINATION coverage, ATTITUDE (Psychology), PNEUMOCOCCAL vaccines, VACCINE hesitancy, HEALTH promotion, DELPHI method
Abstract

Background: Multiple factors, such as less complex U.S. adult pneumococcal recommendations that could increase vaccination rates, childhood pneumococcal vaccination indirect effects that decrease adult vaccination impact, and increased vaccine hesitancy (particularly in underserved minorities), could diminish the cost‐effectiveness of programs to increase pneumococcal vaccination in older adults. Prior analyses supported the economic favorability of these programs. Methods: A Markov model compared no vaccination and current recommendations (either 20‐valent pneumococcal conjugate vaccine [PCV20] alone or 15‐valent pneumococcal conjugate vaccine plus the 23‐valent pneumococcal polysaccharide vaccine [PCV15/PPSV23]) without or with programs to increase vaccine uptake in Black and non‐Black 65‐year‐old cohorts. Pre‐pandemic population‐ and serotype‐specific pneumococcal disease risk and illness/vaccine costs came from U.S. databases. Program costs were $2.19 per vaccine‐eligible person and increased absolute vaccination likelihood by 7.5%. Delphi panel estimates and trial data informed vaccine effectiveness values. Analyses took a healthcare perspective, discounting at 3%/year over a lifetime time horizon. Results: Uptake programs decreased pneumococcal disease overall. In Black cohorts, PCV20 without program cost $216,805 per quality‐adjusted life year (QALY) gained compared with no vaccination; incremental cost‐effectiveness was $245,546/QALY for PCV20 with program and $425,264/QALY for PCV15/PPSV23 with program. In non‐Black cohorts, all strategies cost >$200,000/QALY gained. When considering the potential indirect effects from childhood vaccination, all strategies became less economically attractive. Increased vaccination with less complex strategies had negligible effects. In probabilistic sensitivity analyses, current recommendations with or without programs were unlikely to be favored at thresholds <$200,000/QALY gained. Conclusion: Current U.S. pneumococcal vaccination recommendations for older adults were unlikely to be economically reasonable with or without programs to increase vaccine uptake. Alternatives to current pneumococcal vaccines that include pneumococcal serotypes associated with adult disease should be considered. See related Editorial by Melissa K. Andrew in this issue. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Anti–SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021–June 2022.

Author

Sumner, Kelsey M, Yadav, Ruchi, Noble, Emma K, Sandford, Ryan, Joshi, Devyani, Tartof, Sara Y, Wernli, Karen J, Martin, Emily T, Gaglani, Manjusha, Zimmerman, Richard K, Talbot, H Keipp, Grijalva, Carlos G, Belongia, Edward A, Chung, Jessie R, Rogier, Eric, Coughlin, Melissa M, and Flannery, Brendan

Subjects
COVID-19, COVID-19 pandemic, VACCINE effectiveness, INFLUENZA vaccines, PROTEIN receptors
Abstract

Background We assessed associations between binding antibody (bAb) concentration <5 days from symptom onset and testing positive for COVID-19 among patients in a test-negative study. Methods From October 2021 to June 2022, study sites in 7 states enrolled patients aged ≥6 months presenting with acute respiratory illness. Respiratory specimens were tested for SARS-CoV-2. In blood specimens, we measured concentrations of anti-SARS-CoV-2 antibodies against the spike protein receptor binding domain (RBD) and nucleocapsid antigens from the ancestral strain in standardized bAb units (BAU). Percentage change in odds of COVID-19 by increasing anti-RBD bAb was estimated via logistic regression as (1 – adjusted odds ratio of COVID-19) × 100, adjusting for COVID-19 mRNA vaccine doses, age, site, and high-risk exposure. Results Out of 2018 symptomatic patients, 662 (33%) tested positive for acute SARS-CoV-2 infection. Geometric mean RBD bAb levels were lower among COVID-19 cases than SARS-CoV-2 test-negative controls during the Delta-predominant period (112 vs 498 BAU/mL) and Omicron-predominant period (823 vs 1189 BAU/mL). Acute-phase ancestral spike RBD bAb levels associated with 50% lower odds of COVID-19 were 1968 BAU/mL against Delta and 3375 BAU/mL against Omicron; thresholds may differ in other laboratories. Conclusions During acute illness, antibody concentrations against ancestral spike RBD were associated with protection against COVID-19. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Antibody Response to Symptomatic Infection With SARS‐CoV‐2 Omicron Variant Viruses, December 2021–June 2022.

Author

Sandford, Ryan, Yadav, Ruchi, Noble, Emma K., Sumner, Kelsey, Joshi, Devyani, Tartof, Sara Y., Wernli, Karen J., Martin, Emily T., Gaglani, Manjusha, Zimmerman, Richard K., Talbot, H. Keipp, Grijalva, Carlos G., Belongia, Edward A., Carlson, Christina, Coughlin, Melissa, Flannery, Brendan, Pearce, Brad, and Rogier, Eric

Subjects
SARS-CoV-2 Omicron variant, ANTIBODY formation, HUMORAL immunity, PROTEIN receptors, ACUTE diseases, DEEP brain stimulation
Abstract

We describe humoral immune responses in 105 ambulatory patients with laboratory‐confirmed SARS‐CoV‐2 Omicron variant infection. In dried blood spot (DBS) collected within 5 days of illness onset and during convalescence, we measured binding antibody (bAb) against ancestral spike protein receptor binding domain (RBD) and nucleocapsid (N) protein using a commercial multiplex bead assay. Geometric mean bAb concentrations against RBD increased by a factor of 2.5 from 1258 to 3189 units/mL and by a factor of 47 against N protein from 5.5 to 259 units/mL between acute illness and convalescence; lower concentrations were associated with greater geometric mean ratios. Paired DBS specimens may be used to evaluate humoral response to SARS‐CoV‐2 infection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Interim Estimates of 2019–20 Seasonal Influenza Vaccine Effectiveness — United States, February 2020

Author

Dawood, Fatimah S., Chung, Jessie R., Kim, Sara S., Zimmerman, Richard K., Nowalk, Mary Patricia, Jackson, Michael L., Jackson, Lisa A., Monto, Arnold S., Martin, Emily T., Belongia, Edward A., McLean, Huong Q., Gaglani, Manjusha, Dunnigan, Kayan, Foust, Angie, Sessions, Wendy, DaSilva, Juliana, Le, Shoshona, Stark, Thomas, Kondor, Rebecca J., Barnes, John R., Wentworth, David E., Brammer, Lynnette, Fry, Alicia M., Patel, Manish M., and Flannery, Brendan

Published
2020

20. Differential Induction of Interferon-Stimulated Genes by Cell-Based Versus Egg-Based Quadrivalent Influenza Vaccines in Children During the 2018–2019 Season.

Author

Martin, Judith M, Geffel, Krissy Moehling, Ortiz, Marianna A, Rajasundaram, Dhivyaa, Nowalk, Mary Patricia, Zimmerman, Richard K, and Alcorn, John F

Subjects
INFLUENZA vaccines, VACCINATION of children, MONONUCLEAR leukocytes, VIRAL shedding, SEROCONVERSION, VACCINE effectiveness, GENETIC regulation
Abstract

Background Cell-based quadrivalent-inactivated influenza vaccine has been shown to have higher vaccine effectiveness than traditional egg-based quadrivalent-inactivated influenza vaccine. This is observed despite similar levels of serum hemagglutinin antibodies induced by each vaccine. Methods In this study, we examine peripheral immune activation after egg-based or cell-based influenza vaccination in a clinical trial in children. Peripheral blood mononuclear cells were isolated, and ribonucleic acid was sequenced from 81 study participants (41 Fluzone, egg based and 40 Flucelvax, cell based) pre- and 7 days postvaccination. Seroconversion was assessed by hemagglutinin inhibition assay. Differential gene expression was determined and pathway analysis was conducted. Results Cell-based influenza vaccine induced greater interferon-stimulated and innate immune gene activation compared with egg-based influenza vaccine. Participants who seroconverted had increased interferon-signaling activation versus those who did not seroconvert. Conclusions These data suggest that cell-based influenza vaccine stimulates immune activation differently from egg-based influenza vaccine, shedding light on reported differences in vaccine effectiveness. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. 1161. Effectiveness of the Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Infections in Outpatient Immunocompromised Adults, 2017-2018

Author

Kramer, Kailey Hughes, primary, Zimmerman, Richard K, additional, Nowalk, MaryPatricia, additional, Silveira, Fernanda P, additional, Balasubramani, G K, additional, Chung, Jessie R, additional, Belongia, Edward, additional, Martin, Emily T, additional, Gaglani, Manjusha, additional, Haggerty, Catherine L, additional, and Phillips, C Hallie, additional

Published
2023
Full Text
View/download PDF

22. Antibody response to symptomatic infection with SARS-CoV-2 Omicron variant viruses, December 2021—June 2022

Author

Sandford, Ryan, primary, Yadav, Ruchi, additional, Noble, Emma K., additional, Sumner, Kelsey, additional, Joshi, Devyani, additional, Tartof, Sara Y., additional, Wernli, Karen J., additional, Martin, Emily T., additional, Gaglani, Manjusha, additional, Zimmerman, Richard K., additional, Talbot, H. Keipp, additional, Grijalva, Carlos G., additional, Belongia, Edward A., additional, Carlson, Christina, additional, Coughlin, Melissa, additional, Flannery, Brendan, additional, Pearce, Brad, additional, and Rogier, Eric, additional

Published
2023
Full Text
View/download PDF

25. Interim Estimates of 2018–19 Seasonal Influenza Vaccine Effectiveness — United States, February 2019

Author

Doyle, Joshua D., Chung, Jessie R., Kim, Sara S., Gaglani, Manjusha, Raiyani, Chandni, Zimmerman, Richard K., Nowalk, Mary Patricia, Jackson, Michael L., Jackson, Lisa A., Monto, Arnold S., Martin, Emily T., Belongia, Edward A., McLean, Huong Q., Foust, Angie, Sessions, Wendy, Berman, LaShondra, Garten, Rebecca J., Barnes, John R., Wentworth, David E., Fry, Alicia M., Patel, Manish M., and Flannery, Brendan

Published
2019

27. Paid Leave and Access to Telework as Work Attendance Determinants during Acute Respiratory Illness, United States, 2017-2018

Author

Ahmed, Faruque, Kim, Sara, Nowalk, Mary Patricia, King, Jennifer P., VanWormer, Jeffrey J., Gaglani, Manjusha, Zimmerman, Richard K., Bear, Todd, Jackson, Michael L., Jackson, Lisa A., Martin, Emily, Cheng, Caroline, Flannery, Brendan, Chung, Jessie R., and Uzicanin, Amra

Subjects
United States. Centers for Disease Control and Prevention, Influenza -- Comparative analysis, Telecommuting -- Comparative analysis, Retirement benefits, Workers, Respiratory tract diseases, Diseases, Telecommuting, Health
Abstract

The annual economic burden of influenza in the United States, depending on the severity of the influenza season, ranges from $15 billion to $64 billion, of which lost productivity accounts [...]

Published
2020
Full Text
View/download PDF

28. Anti-SARS-CoV-2 Antibody Levels Associated with COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu VE Network, October 2021–June 2022

Author

Sumner, Kelsey M., primary, Yadav, Ruchi, additional, Noble, Emma K., additional, Sandford, Ryan, additional, Joshi, Devyani, additional, Tartof, Sara Y., additional, Wernli, Karen J., additional, Martin, Emily T., additional, Gaglani, Manjusha, additional, Zimmerman, Richard K., additional, Talbot, H. Keipp, additional, Grijalva, Carlos G., additional, Chung, Jessie R., additional, Rogier, Eric, additional, Coughlin, Melissa M., additional, and Flannery, Brendan, additional

Published
2023
Full Text
View/download PDF

30. Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications During 5 Influenza Seasons—United States, 2011–2016

Author

Stewart, Rebekah J., Flannery, Brendan, Chung, Jessie R., Gaglani, Manjusha, Reis, Michael, Zimmerman, Richard K., Nowalk, Mary Patricia, Jackson, Lisa, Jackson, Michael L., Monto, Arnold S., Martin, Emily T., Belongia, Edward A., McLean, Huong Q., Fry, Alicia M., and Havers, Fiona P.

Published
2018

40. A randomized controlled trial to compare immunogenicity to cell-based vs. live-attenuated influenza vaccines in children

Author

Williams, Katherine V, primary, Li, Zhu-Nan, additional, Zhai, Bo, additional, Alcorn, John F, additional, Nowalk, Mary Patricia, additional, Levine, Min Z, additional, Kim, Sara S, additional, Flannery, Brendan, additional, Moehling Geffel, Krissy, additional, Merranko, Amanda Jaber, additional, Collins, Mark, additional, Susick, Michael, additional, Clarke, Karen S, additional, Zimmerman, Richard K, additional, and Martin, Judith M, additional

Published
2023
Full Text
View/download PDF

41. Seasonal Influenza in Adults and Children—Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America

Author

Harper, Scott A, Bradley, John S, Englund, Janet A, File, Thomas M, Gravenstein, Stefan, Hayden, Frederick G, McGeer, Allison J, Neuzil, Kathleen M, Pavia, Andrew T, Tapper, Michael L, Uyeki, Timothy M, and Zimmerman, Richard K

Subjects
Infectious Diseases, Vaccine Related, Emerging Infectious Diseases, Influenza, Pneumonia & Influenza, Prevention, Clinical Research, Biodefense, Infection, Good Health and Well Being, Adult, Antiviral Agents, Chemoprevention, Child, Disease Management, Disease Outbreaks, Guideline Adherence, Humans, Influenza, Human, Risk Factors, Seasons, Expert Panel of the Infectious Diseases Society of America, Biological Sciences, Medical and Health Sciences, Microbiology
Abstract

Guidelines for the treatment of persons with influenza virus infection were prepared by an Expert Panel of the Infectious Diseases Society of America. The evidence-based guidelines encompass diagnostic issues, treatment and chemoprophylaxis with antiviral medications, and issues related to institutional outbreak management for seasonal (interpandemic) influenza. They are intended for use by physicians in all medical specialties with direct patient care, because influenza virus infection is common in communities during influenza season and may be encountered by practitioners caring for a wide variety of patients.

Published
2009

45. Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015

Author

Flannery, Brendan, Zimmerman, Richard K., Gubareva, Larisa V., Garten, Rebecca J., Chung, Jessie R., Nowalk, Mary Patricia, Jackson, Michael L., Jackson, Lisa A., Monto, Arnold S., Ohmit, Suzanne E., Belongia, Edward A., McLean, Huong Q., Gaglani, Manjusha, Piedra, Pedro A., Mishin, Vasiliy P., Chesnokov, Anton P., Spencer, Sarah, Thaker, Swathi N., Barnes, John R., Foust, Angie, Sessions, Wendy, Xu, Xiyan, Katz, Jacqueline, and Fry, Alicia M.

Published
2016

49. Blood Inflammatory Biomarkers Differentiate Inpatient and Outpatient Coronavirus Disease 2019 From Influenza

Author

Luciani, Lauren L, primary, Miller, Leigh M, additional, Zhai, Bo, additional, Clarke, Karen, additional, Hughes Kramer, Kailey, additional, Schratz, Lucas J, additional, Balasubramani, G K, additional, Dauer, Klancie, additional, Nowalk, M Patricia, additional, Zimmerman, Richard K, additional, Shoemaker, Jason E, additional, and Alcorn, John F, additional

Published
2023
Full Text
View/download PDF

50. Prevalence and Clinical Outcomes of Respiratory Syncytial Virus versus Influenza in Adults Hospitalized with Acute Respiratory Illness from a Prospective Multicenter Study

Author

Begley, Katherine M, primary, Monto, Arnold S, additional, Lamerato, Lois E, additional, Malani, Anurag N, additional, Lauring, Adam S, additional, Talbot, H Keipp, additional, Gaglani, Manjusha, additional, McNeal, Tresa, additional, Silveira, Fernanda P, additional, Zimmerman, Richard K, additional, Middleton, Donald B, additional, Ghamande, Shekhar, additional, Murthy, Kempapura, additional, Kim, Lindsay, additional, Ferdinands, Jill M, additional, Patel, Manish M, additional, and Martin, Emily T, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results